Vaccination paradox in bluetongue control
DOI:
https://doi.org/10.66585/ohmi.2026.2.0018Schlagwörter:
Bluetongue, Cattle, Sheep, Vaccine, Vector, VirusAbstract
The bluetongue virus (BTV) is the causative agent of bluetongue, a non-contagious viral disease affecting ruminants. It is transmitted by insects of the Culicoides genus. The disease's complexity is reflected in the large number of recognized serotypes. Bluetongue can be particularly severe in sheep, causing symptoms such as fever, facial edema, cyanosis of the tongue, oral lesions, lameness, and high mortality. Cattle serve as a subclinical reservoir. Controlling BTV is a crucial challenge in livestock farming, requiring the identification of innovative vaccination strategies that induce effective immunity against the various circulating serotypes. In this context, the "vaccine paradox" of BTV emerges, revealing a discrepancy between the proven immunological efficacy of available vaccines and their inability to ensure stable epidemiological control. This paper investigates the reasons for this discrepancy and clarifies the structural limitations that prevent current vaccination strategies from achieving this.
Literaturhinweise
1. Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marín-López A. Recombinant vaccines against bluetongue virus. Virus Res. 2014;182:78-86. https://doi.org/10.1016/j.virusres.2013.11.013
2. Barua S, Rana EA, Prodhan MA, Akter SH, Gogoi-Tiwari J, Sarker S, et al. The global burden of emerging and re-emerging orbiviruses in livestock: An emphasis on bluetongue virus and epizootic hemorrhagic disease virus. Viruses. 2025;17(1):20. https://doi.org/
10.3390/v17010020
3. Roy P. Bluetongue virus structure and assembly. Curr Opin Virol. 2017;24:115-123. https://doi.org/10.1016/j.coviro.2017.05.003
4. Zhang X, Boyce M, Bhattacharya B, Zhang X, Schein S, Roy P, et al. Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Proc Natl Acad Sci U S A. 2010;107(14):6292-6297. https://doi.org/10.1
073/pnas.0913403107
5. Martinez-Costas J, Sutton G, Ramadevi N, Roy P. Guanylyltransferase and RNA 5′-triphosphatase activities of the purified expressed VP4 protein of bluetongue virus. J Mol Biol. 1998;280(5):859-866. https://doi.org/10.1006/jmbi.1998.1926
6. Limn CK, Roy P. Intermolecular interactions in a two-layered viral capsid that requires a complex symmetry mismatch. J Virol. 2003;77(20):11114-11124. https://doi.org/10.1128/JVI.77.20.11114-11124.2003
7. Ul-Rahman A, Shabbir MZ, Wensman JJ. Bluetongue virus in carnivores: Expanding the host range and implications for disease ecology. Vet Q. 2025;45(1):2588740. https://doi.org/10.1080/01652176.2025.2588740
8. Kar S, Mondal B, Pal A, Mazumdar A. Molecular identification of Culicoides oxystoma and Culicoides actoni vectors of bluetongue virus. Med Vet Entomol. 2023;37(3):534-541. https://doi.org/10.1111/mve.12651
9. Ayuti SR, Khairullah AR, Lamid M, Warsito SH, Al Arif MA, Kim EJ, et al. Bluetongue in ruminants: Global epidemiology, pathogenesis, and advances in diagnostic and control strategies within a One Health framework. Vet World. 2025;18(10):3070-3093. https://doi.
org/10.14202/vetworld.2025.3070-3093
10. Guis H, Caminade C, Calvete C, Morse AP, Tran A, Baylis M. Modelling the effects of past and future climate on the risk of bluetongue emergence in Europe. J R Soc Interface. 2012;9(67):339-350. https://doi.org/10.1098/rsif.2011.0255
11. Jenckel M, Bréard E, Schulz C, Sailleau C, Viarouge C, Hoffmann B, et al. Complete coding genome sequence of putative novel bluetongue virus serotype 27. Genome Announc. 2015;3(2):e00016-15. https://doi.org/10.1128/genomeA.00016-15
12. European Parliament, Council of the European Union. Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health (Animal Health Law). Off J Eur Union. 2016;84:1-208. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A3
2016R0429. Accessed 2026 May 13.
13. Department for Environment, Food and Rural Affairs, Animal and Plant Health Agency. Bluetongue virus in Europe: Updated outbreak assessment #13. London. Department for Environment, Food and Rural Affairs. 2025. Available from: https://assets.publishing.service.gov.uk/media/689eea3f2e8cc8ec5b3572be/BTV_Europe_Aug_2025.pdf
14. Bissett SL, Roy P. Impact of VP2 structure on antigenicity: Comparison of BTV1 and the highly virulent BTV8 serotype. J Virol. 2024;98(10):e00953-24. https://doi.org/10.1128/jvi.00953-24
15. Fay PC, Mohd Jaafar F, Batten C, Attoui H, Saunders K, Lomonossoff GP, et al. Serological cross-reactions between expressed VP2 proteins from different bluetongue virus serotypes. Viruses. 2021;13(8):1455. https://doi.org/10.3390/v13081455
16. Joubair I, Errabbani A, Daif S, Zueco J, Bounou S, Fassi Fihri O, et al. Bluetongue in the Mediterranean Basin: An overview of recent hotspots and advances in vaccine technologies. Microorganisms. 2026;14(2):437. https://doi.org/10.3390/microorganisms14020437
17. Dungu B, Gerdes T, Smit T. The use of vaccination in the control of bluetongue in southern Africa. Vet Ital. 2004;40(4):616-622.
18. Wäckerlin R, Eschbaumer M, König P, Hoffmann B, Beer M. Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle. Vaccine. 2010;28(27):4348-4355. https://doi.org/10.1016/j.vaccine.2010.04.055
19. European Medicines Agency. Bluevac BTV: European public assessment report (EPAR). 2011. Available from: https://www.ema.
europa.eu/en/medicines/veterinary/EPAR/bluevac-btv. Accessed 2026 May 13.
20. European Medicines Agency. Bovilis BTV8: European public assessment report (EPAR). Available from: https://www.ema.europ
a.eu/en/medicines/veterinary/EPAR/bovilis-btv8. Accessed 2026 May 13.
21. European Medicines Agency. VeroBlue-3: CVMP summary of positive opinion. 2026. Available from: https://www.ema.europa.eu
/en/medicines/veterinary/EPAR/veroblue-3. Accessed 2026 May 13.
22. European Medicines Agency. BTVPUR ALSAP 8: European public assessment report (EPAR). 2010. Available from: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/btvpur-alsap-8. Accessed 2026 May 13.
23. European Medicines Agency. Zulvac BTV: European public assessment report (EPAR). Available from: https://www.ema.europ
a.eu/en/medicines/veterinary/EPAR/zulvac-btv. Accessed 2026 May 13.
24. European Medicines Agency. Syvazul BTV 3: European public assessment report (EPAR). 2025. Available from: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/syvazul-btv-3. Accessed 2026 May 13.
25. Veterinary Medicines Directorate. BULTAVO 3 suspension for injection for sheep and cattle: Summary of product characteristics. Available from: https://www.vmd.defra.gov.uk/productinformation
database/files/SPC_Documents/SPC_2996252.PDF. Accessed 2026 May 13.
26. Mlingo TAM, O’Kennedy MM, Matsiela M, Nkomo N, Coetzee P, Rametse T, et al. Safety and efficacy of plant-produced trivalent virus-like particle vaccine candidate against bluetongue disease. Plant Biotechnol J. 2026;24(1):273-283. https://doi.org/10.1111/p
bi.70316
27. MacLachlan NJ. The pathogenesis and immunology of bluetongue virus infection of ruminants. Comp Immunol Microbiol Infect Dis. 1994;17(3-4):197-206. https://doi.org/10.1016/0147-9571(94)90043-4
28. MacLachlan NJ, Guthrie AJ. Re-emergence of bluetongue, African horse sickness, and other Orbivirus diseases. Vet Res. 2010;41(6):35. https://doi.org/10.1051/vetres/2010007
29. Caporale M, Di Gialleonardo L, Janowicz A, Wilkie G, Shaw A, Savini G, et al. Virus and host factors affecting the clinical outcome of bluetongue virus infection. J Virol. 2014;88(18):10399-10411. https://doi.org/10.1128/JVI.01641-14
30. Carpenter S, Groschup MH, Garros C, Felippe-Bauer ML, Purse BV. Culicoides biting midges, arboviruses and public health in Europe. Antiviral Res. 2013;100(1):102-113. https://doi.org/10.1016/j.antiviral.2013.07.020
31. Campbell CL, Vandyke KA, Letchworth GJ, Drolet BS, Hanekamp T, Wilson WC. Midgut and salivary gland transcriptomes of the arbovirus vector Culicoides sonorensis (Diptera: Ceratopogonidae). Insect Mol Biol. 2005;14(2):121-136. https://doi.org/10.1111/j.13
65-2583.2004.00537.x
32. Xia X, Wu W, Cui Y, Roy P, Zhou ZH. Bluetongue virus capsid protein VP5 perforates membranes at low endosomal pH during viral entry. Nat Microbiol. 2021;6(11):1424-1432. https://doi.org/10.1038/s41564-021-00988-8
33. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101-105. https://doi.org/10.1038/nature04734
34. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2008;82(1):335-345. https://doi.org/10.1128/JVI.01080-07
35. Yu YQ, Zielinska M, Li W, Bernkopf DB, Heilingloh CS, Neurath MF, et al. PGAM5-MAVS interaction regulates TBK1/IRF3-dependent antiviral responses. Sci Rep. 2020;10(1):8323. https://doi.org/10.1038/s41598-020-65155-1
36. Chauveau E, Doceul V, Lara E, Bréard E, Sailleau C, Vidalain PO, et al. NS3 of bluetongue virus interferes with the induction of type I interferon. J Virol. 2013;87(14):8241-8246. https://doi.org/10.1128/JVI.00678-13
37. Bréard E, Belbis G, Hamers C, Moulin V, Lilin T, Moreau F, et al. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats. Vaccine. 2011;29(13):2495-2502. https://doi.org/10.1016/j.
vaccine.2010.12.105
38. Brand SPC, Keeling MJ. The impact of temperature changes on vector-borne disease transmission: Culicoides midges and bluetongue virus. J R Soc Interface. 2017;14(128):20160481. https://doi.org/10.1098/rsif.2016.0481
39. Carpenter M, Kopanke J, Lee J, Rodgers C, Reed K, Sherman TJ, et al. Evaluating temperature effects on bluetongue virus serotype 10 and 17 coinfection in Culicoides sonorensis. Int J Mol Sci. 2024;25(5):3063. https://doi.org/10.3390/ijms25053063
40. Tugwell LA, England ME, Gubbins S, Sanders CJ, Stokes JE, Stoner J, et al. Thermal limits for flight activity of field-collected Culicoides in the United Kingdom defined under laboratory conditions. Parasit Vectors. 2021;14(1):55. https://doi.org/10.1186/s13071-020-04552-x
41. van Rijn PA. Prospects of next-generation vaccines for bluetongue. Front Vet Sci. 2019;6:407. https://doi.org/10.3389/fvets.2019.00407
42. World Organisation for Animal Health. Chapter 3.1.3. Bluetongue (infection with bluetongue virus). 2021. Available from: https://www.woah.org/fileadmin/Home/fr/Health_standards/tahm/3.01.03_BLUETONGUE.pdf. Accessed 2026 May 13.
43. World Organisation for Animal Health. Chapter 8.3. Infection with bluetongue virus. In: Terrestrial Animal Health Code. 2024. Available from: https://www.woah.org/fileadmin/Home/eng/Healt
h_standards/tahc/2024/en_chapitre_bluetongue.htm. Accessed 2026 May 13.
44. Holwerda M, Santman-Berends IMGA, Harders F, Engelsma M, Vloet RPM, Dijkstra E, et al. Emergence of bluetongue virus serotype 3, the Netherlands, September 2023. Emerg Infect Dis. 2024;30(8):1552-1561. https://doi.org/10.3201/eid3008.231331
45. Van Leeuw V, De Leeuw I, Degives N, Depoorter P, Dewulf J, Hanon JB, et al. Impact of BTV-3 circulation in Belgium in 2024 and current knowledge gaps hindering an evidence-based control program. Viruses. 2025;17(4):521. https://doi.org/10.3390/v17040521
46. van den Brom R, Santman-Berends I, van der Heijden MG, Harders F, Engelsma M, van Gennip RGP, et al. Bluetongue virus serotype 12 in sheep and cattle in the Netherlands in 2024: A BTV serotype reported in Europe for the first time. Vet Microbiol. 2025;301:110365. https://doi.org/10.1016/j.vetmic.2024.110365
47. Jiménez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Lorenzo G, Illescas-Amo M, Benavides J, et al. Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus. Front Immunol. 2024;15:1440407. https://doi.org/10.3389/fimmu.2024.1440407
48. Jiménez-Cabello L, Utrilla-Trigo S, Illescas-Amo M, Rodríguez-Sabando K, Benavides-Silván J, Calvo-Pinilla E, et al. The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus. Front Immunol. 2025;16:1566225. https://doi.org/10.3389/fimmu.2025.1566225
Veröffentlicht
Ausgabe
Rubrik
Lizenz
Copyright (c) 2026 Anna C. Procopio, Alessio Soggiu, Mariachiara Paonessa, Emanuela Laratta, Hany A. Hussein, Paola Roncada (Author)
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung - Nicht-kommerziell 4.0 International.
